Kopf- & Halstumoren

Prof. Dr. Barbara Wollenberg

Psyrri A et al. Molecular correlates of response to preoperative olaparib alone or with cisplatin or with durvalumab in head and neck squamous cell carcinoma (HNSCC): A Hellenic Cooperative Oncology Group study.
Bernal MO et al. SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study.
Zinner R et al. Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer.

PD Dr. Markus Hecht

Hecht M et al. A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).
Bahig H et al. Initial analyses of a phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma.
Klinghammer KF et al. DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.
Johnson JM et al. Nivolumab (Nivo) and ipilimumab (Ipi) in combination with radiotherapy (RT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

PD Dr. Sebastian Ochsenreither

Chung CH et al. Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
Cohen RB et al. Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.
Angevin E et al. Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).
Hansen AR et al. INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell costimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Siu LL et al. Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck cquamous cell carcinoma (HNSCC).

Kopf- & Halstumoren Highlight

404 Not Found

Die Seite wurde leider nicht gefunden

Gründe dafür könnten sein, dass Sie eine falsche oder veraltete URL aufgerufen haben. Oder aber die Seite wurde von uns umbenannt, verschoben und archiviert. Versuchen Sie es noch einmal und aktualisieren Sie die Seite.

Andernfalls verwenden Sie bitte den folgenden Link, um die von Ihnen gewünschten Inhalte zu finden

Zur Startseite